Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
GSK's ADC Drug for Lung Cancer Gets FDA's Breakthrough Tag
11:20am, Tuesday, 20'th Aug 2024
The FDA bestows a Breakthrough Therapy Designation to GSK's B7-H3-targeted antibody-drug conjugate, GSK5764227, for relapsed/refractory extensive-stage small-cell lung cancer.
GSK gets fast-track approval from FDA for Chinese lung cancer drug
02:37am, Tuesday, 20'th Aug 2024
GSK PLC (LSE:GSK, NYSE:GSK) has received the green light for a speedier US regulatory process for a potential new cancer drug being developed with a Chinese partner. The pharmaceuticals developer sa
Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings
01:57pm, Monday, 19'th Aug 2024
In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comp
GSK's discount unwarranted, especially with latest Zantac win, says broker
08:51am, Friday, 16'th Aug 2024
British pharma multinational GSK PLC (LSE:GSK, NYSE:GSK) has persistently been undervalued against its international peer set due to merited fears over the high-profile Zantac litigation. But with rec
GSK to seek dismissal of Florida case against heartburn drug Zantac
04:42am, Friday, 16'th Aug 2024
British drugmaker GSK said on Friday it would seek a dismissal of an upcoming Zantac case in Florida, where plaintiffs alleged that its discontinued heart burn drug had caused prostate cancer.
GSK wins favourable ruling in US Zantac litigation
02:50am, Friday, 16'th Aug 2024
GSK PLC (LSE:GSK, NYSE:GSK) has secured a legal victory in the ongoing Zantac (ranitidine) litigation, with the Florida State court in the US excluding the plaintiffs' expert testimony as unreliable.
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
07:30am, Thursday, 15'th Aug 2024
Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's mRNA platform Initiated strategic workforce reduction of
GSK (GSK) is a Top-Ranked Momentum Stock: Should You Buy?
10:50am, Tuesday, 13'th Aug 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
09:00am, Monday, 12'th Aug 2024
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high
German panel endorses GSK, Pfizer RSV vaccines for elderly
09:18am, Thursday, 08'th Aug 2024
Germany's influential vaccine advisory panel said on Thursday that everyone in the country who is 75-years old or more should receive one of two new vaccines against the common respiratory infection R
Dividend Income: Lanny's July 2024 Summary
08:35am, Tuesday, 06'th Aug 2024
In July, we (my wife and I) received a dividend income total of $2,836.82. 2023 was up 24%. 7 months down in 2024 and the S&P 500 is still up almost 13%, despite the recent sell-offs. We have a high l
GSK wins Illinois court battle
02:28am, Tuesday, 06'th Aug 2024
GSK PLC (LSE:GSK, NYSE:GSK) has successfully refuted claims that its discontinued heartburn drug Zantac caused cancer after an Illinois jury found that the product was not responsible for plaintiff Ca
GSK wins latest trial over Zantac cancer claims
05:52pm, Monday, 05'th Aug 2024
GSK won the latest trial over claims that discontinued heartburn drug Zantac caused cancer, as a jury on Monday found that the drug was not responsible for an Illinois woman's illness, a company spoke
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
02:22pm, Friday, 02'nd Aug 2024
On Thursday, Moderna Inc MRNA lowered its 2024 sales guidance due to weaker demand for its COVID-19 vaccines.
India's GlaxoSmithKline Pharma posts higher Q1 adjusted profit on strong demand
06:35am, Friday, 02'nd Aug 2024
India's GlaxoSmithKline Pharmaceuticals reported a higher first-quarter adjusted profit on Friday, driven by strong demand for its generic drugs and vaccines.
